This contact lens can treat glaucoma automatically

Publicly released:
International
Photo by Adrian Gordon on Unsplash
Photo by Adrian Gordon on Unsplash

Researchers have developed a contact lens that can treat glaucoma by sensing when treatment is needed and applying it. The team says damage from glaucoma is often caused by pressure in the eye which can vary throughout the day, making it difficult to treat appropriately. The lens, they say, is able to use electrical sensing to measure pressure in the eye and deliver a glaucoma treatment drug whenever it's needed. While further research is needed, the team says this device could one day be manufactured cost-effectively.

Media release

From: Springer Nature

Biotechnology: Contact lens measures pressure and delivers glaucoma drug

A contact lens capable of wireless intraocular pressure sensing and on-demand anti-glaucoma drug delivery, is reported in Nature Communications. The device is flexible and battery-free, with a compact design, and may be a promising system for the treatment of glaucoma.

Glaucoma (and its associated diseases) can cause irreversible vision loss, with damage often caused by an increase of intraocular pressure due to the abnormal circulation of fluid within the eye. This pressure can vary with human activities and circadian rhythm, which makes treatment challenging as it requires the long-term and continuous tracking of the eye’s condition. Theranostic devices — which combine therapeutics and diagnostics — are capable of monitoring a determined condition and applying an appropriate treatment.

Xi Xie, Cheng Yang and colleagues developed a theranostic contact lens, which uses electrical sensing to measure intraocular pressure and can deliver a drug on demand. The device was tested in porcine and rabbit eyes and was able to detect changes in intraocular pressure. When the measured intraocular pressure reaches a high-risk level, the drug delivery module (powered by wireless power transfer) has the ability to trigger delivery of an anti-glaucoma drug into the anterior chamber of the eye across corneal barriers.

The authors suggest that fabrication of the device is compatible with existing large-scale and cost-effective manufacturing processes. However, they indicate that further research is needed before it can move towards clinical tests.

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research Springer Nature, Web page The URL will go live after the embargo ends
Journal/
conference:
Nature Communications
Research:Paper
Organisation/s: Sun Yat-Sen University, China
Funder: The authors would like to acknowledge financial support from the National Key R&D Program of China (Grant No. 2021YFF1200700 and 2021YFA0911100), the National Natural Science Foundation of China (Grant No. 32171399, 32171456, 32171335, 61901535, 31900954, and 62104264), Science and Technology Program of Guangzhou, China (Grant No. 202102080192, and 202103000076), Guangdong Basic and Applied Basic Research Foundation (Grant No. 2019A1515012087, 2020A1515110940, and 2021A1515012261), and Pazhou Lab, Guangzhou (P2L2021KF0003).
Media Contact/s
Contact details are only visible to registered journalists.